Shilpa Medicare informs about company updates

13 Dec 2016 Evaluate

Shilpa Medicare has informed that the Company has received an approval from the United States Food & Drug Administration (USFDA) (the Office of Bioequivalence) for Capecitabine Tablets USP, 150 mg and 500 mg to be bioequivalent and therapeutically equivalent to the reference listed drug product (RLD), Xeloda Tablets, 150 mg and 500 mg of Hoffmann-La Roche, Inc.

The above information is a part of company’s filings submitted to BSE.

Shilpa Medicare Share Price

911.00 -24.80 (-2.65%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.